drugset / Trial / NCT03983928
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.
Timeline
- Start
- 2019-06-03
- Primary completion
- 2020-10-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |